Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in .
Oxurion NVApril 12, 2021 GMT
Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Association for Cancer Research (AACR).
The data was presented by Dr. Giselle Sholler, Director, Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Paediatric Oncology at the Levine Children’s Hospital in Charlotte, NC.
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR . | April 11, 2021
email article
Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed.
The pCR rate increased from 2.2% with chemotherapy alone to 24.0% with the addition of nivolumab. The between-group difference increased in an analysis limited to patients who had complete resection. Clearance of circulating tumor (ct) DNA during neoadjuvant therapy increased the likelihood of pCR, reported Patrick M. Forde, MD, of the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, at the American Association for Cancer Research (AACR) virtual meeting. CheckMate 816 showed a statistically significant improvement in pCR, said Forde. This benefit was consistent across disease stages, histology, TMB (tumor mutational burden) and PD-L1 expression. The study continues to mature for the event-free survival (EFS) primary endpoint.
email article
An immunotherapy combination for metastatic castration-resistant prostate cancer (mCRPC) failed to hit a response target but still exceeded historical results, a small prospective study showed.
Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel.
The safety profile of the combination was consistent with prior clinical experience, reported Mark Linch, MD, PhD, of University College London, at the American Association for Cancer Research virtual meeting. Responders were enriched with patients with mismatch repair or BRCA 1 and 2, said Linch. We believe that further study of nivolumab and ipilimumab i biomarker-selected patients with metastatic castration-resistant prostate cancer is warranted. The rate of incomplete treatment was high,
London [UK], April 12 (ANI): The findings of recent research from Queen Mary University of London revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME).